Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
Hemab Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Hemab Therapeutics
Hemab Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?